Cargando…

Dynamic host immune response in virus-associated cancers

Viruses drive carcinogenesis in human cancers through diverse mechanisms that have not been fully elucidated but include promoting immune escape. Here we investigated associations between virus-positivity and immune pathway alteration for 2009 tumors across six virus-related cancer types. Analysis r...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Song, Wylie, Kristine M., Wyczalkowski, Matt A., Karpova, Alla, Ley, Jessica, Sun, Sam, Mashl, R. Jay, Liang, Wen-Wei, Wang, Xiaowei, Johnson, Kimberly, DiPersio, John F., Gay, Hiram, Ratner, Lee, Chen, Feng, Adkins, Douglas R., Ding, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430765/
https://www.ncbi.nlm.nih.gov/pubmed/30911684
http://dx.doi.org/10.1038/s42003-019-0352-3
Descripción
Sumario:Viruses drive carcinogenesis in human cancers through diverse mechanisms that have not been fully elucidated but include promoting immune escape. Here we investigated associations between virus-positivity and immune pathway alteration for 2009 tumors across six virus-related cancer types. Analysis revealed that for 3 of 72 human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSC) the HPV genome integrated in immune checkpoint genes PD-L1 or PD-L2, driving elevated expression in the corresponding gene. In addition to the previously described upregulation of the PD-1 immunosuppressive pathway in Epstein-Barr virus (EBV)-positive stomach tumors, we also observed upregulation of the PD-1 pathway in cytomegalovirus (CMV)-positive tumors. Furthermore, we found signatures of T-cell and B-cell response in HPV-positive HNSC and EBV-positive stomach tumors and HPV-positive HNSC patients were associated with better survival when T-cell signals were detected. Our work reveals that viral infection may recruit immune effector cells, and upregulate PD-1 and CTLA-4 immunosuppressive pathways.